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Abstract
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority
over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line,
K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a
dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-
resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel
therapy for CML.
To the editor
The BCR/ABL kinase inhibitor, imatinib, is the single
effective and the standard treatment for chronic myeloid
leukemia (CML) [1]. Resistance to imatinib is now a
problem clinically. Imatinib resistance is often attributed
to the emergence of clones expressing the BCR/ABL
mutation and several other mechanisms such as overex-
pression of BCR/ABL and activation of Src-related
kinase [2]. Nilotinib (AMN107) is a new BCR/ABL inhi-
bitor and is highly selective for ABL kinase and 30-fold
more potent than imatinib. Nilotinib has produced
hematological and cytogenetic responses in CML
patients, who did not initially respond to imatinib or
developed imatinib resistance [3]. Recently, in Evaluating
Nilotinib Efficacy and Safety in clinical Trials-newly
diagnosed CML (ENESTnd), nilotinib has shown super-
ior efficacy as front line treatment for patients with
CML-chronic phase (CP) in comparison with imatinib
[4,5]. Although nilotinib has shown superiority over
imatinib in first-line treatment for CML-CP patients,
the management of CML following the development of
nilotinib resistance remains a challenge. In this study,
we established a nilotinib-resistant cell line, K562NR,
and evaluated the resistance to and efficacy of dasatinib.
BCR/ABL levels were not increased by fluorescence in
situ hybridization (FISH) analysis (data not shown).
K562NR cells had no point mutation in Abl kinase (data
not shown). K562 NR cells were resistant to high con-
centrations of nilotinib, with the IC50 being more than
10 μM (Figure 1A). Dasatinib (BMS-354825), a second
generation tyrosine kinase inhibitor, is another promis-
ing new clinical candidate for CML treatment and has
also shown good efficacy in CML patients, including
imatinib-resistant cases. Dasatinib is an effective therapy
after imatinib and nilotinib therapy failure in CML
patients [6]. The phase III dasatinib versus imatinib
study in treatment-naïve CML patients (DASISION)
study demonstrates superior efficacy of dasatinib over
imatinib and an acceptable safety profile [5,7]. We
found that dasatinib reduced the cell growth of K562NR
and significantly induced apoptosis. The IC50 of dasati-
nib is 5 nM (Figure 1A). We found that K562NR cells
underwent increased phosphorylation of Src family
kinase (SFK) including Lyn (Figure 1B). Phosphorylation
of SFK was reduced after 24-hrs dasatinib treatment in
a dose-dependent manner. Cleaved caspase 3 and poly
(ADP-ribose) polymerase (PARP) were detected after
24-hrs dasatinib treatment (Figure 1B). We noted that
protein levels of p21 increased and cyclin D1 was
reduced after dasatinib treatment (Figure 1B). In our
experiment, dasatinib also potentially induced apoptosis
of the nilotinib-resistant cell line. Dasatinib was effective
in 13 of the 23 patients with CML after imatinib and
nilotinib therapy failure, including 7 patients who had a
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cytogenetic response [6]. These patients exhibited sev-
eral Abl kinase mutations such as E255V/K. The resis-
tance to imatinib in BCR/ABL positive cells has been
reported to be associated with the activation of PI3K/
AKT1 pathways [8]. In this study, there was no muta-
tion in Abl kinase, but Src family kinases, including Lyn,
was activated in the nilotinib-resistant cell line. Lyn
kinase has been previously shown to be an important
component in cytokine signal transduction, and is also
reported to play a role in the growth and apoptotic reg-
ulation of hematopoietic cells [9]. Activation of SFK
including Lyn may play a dominant role in the prolifera-
tion and survival of the nilotinib-resistant cell line, and
the reduction of SFK phosphorylation may act at the
p21 and cyclin D1 level and induce the apoptosis of
K562NR cells after dasatinib treatment. This study
Figure 1 Cell growth inhibition by dasatinib and cellular signaling in a nilotinib resistant cell line. (A) K562NR cells exposed to dasatinib
or nilotinib for 72-hrs were quantitated by cell proliferation. Each result is presented as the mean percentage of proliferation of unexposed
control cultures. (B) Phosphorylation of Lyn, Src, cleaved caspase 3, PARP, p21, cyclin D1, and actin levels were analyzed by immunoblotting
using the protein (30 μg) from cell lysates.
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showed that secondary signaling events involving SFK/
Lyn in a nilotinib-resistant CML cell line may play a sig-
nificant role for in the resistant mechanism.
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